Jason Zemansky
Stock Analyst at B of A Securities
(1.29)
# 1851
Out of 5,370 analysts
46
Total ratings
56.25%
Success rate
9.66%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
INSM Insmed | Maintains: Strong Buy | 94 109 | 101.21 | 7.7% | 10 | Jun 11, 2025 | |
KROS Keros Therapeutics | Downgrades: Neutral | 32 18 | 13.57 | 32.65% | 2 | Jun 10, 2025 | |
RCKT Rocket Pharmaceutica... | Maintains: Buy | 32 9 | 2.92 | 208.22% | 1 | May 28, 2025 | |
CYTK Cytokinetics | Maintains: Neutral | 62 54 | 33.35 | 61.92% | 4 | Apr 15, 2025 | |
TVTX Travere Therapeutics | Maintains: Strong Buy | 29 31 | 14.46 | 114.38% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 22 17 | 9.14 | 86% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 29 | 6.44 | 350.31% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 30 31 | 9.98 | 210.62% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 3 3 | 1.16 | 115.52% | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 391 23 | n/a | n/a | 2 | Dec 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 230 | n/a | n/a | 1 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 9 10 | 1.26 | 693.65% | 4 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 450 162 | n/a | n/a | 1 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 145 155 | n/a | n/a | 2 | Dec 13, 2021 |